> Roche has decided not to license an anti-fungal from Basilea, which analysts say could pave the way to a new deal. Report
> Amarin plans to raise $26.4 million through a private placement to support development of Miraxion. Release
> San Diego-based Inovio Biomedical says it will raise $15.8 million through equity funding. Release
> BioAxone has closed the last tranche of a second-round investment of $12.15 million. Release
> The New York Times examines the controversy surrounding the decision by the Canadian Medical Association to squelch a Plan B report in the Canadian Medical Association Journal. Article
> Miami-based Ivax says that it has received final approval for a generic version of the schizophrenia drug Clozaril. Release
> Alnylam Pharmaceuticals of Cambridge, MA, has initiated a Phase I study ALN-RSV01, an RNAi therapeutic for RSV infection. Release
And Finally… In Alaska, long winter nights are linked to high rates of seasonal depression. Article